Scientific Publications by FDA Staff
Clin Infect Dis 2014 Feb;58(4):537-9
Hypersensitivity reactions associated with fidaxomicin use.
Iarikov D, Alexander J, Nambiar S
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea (CDAD). These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed. The fidaxomicin labeling was revised to include information about the possibility of hypersensitivity reactions.
|Category: Journal Article|
|PubMed ID: #24178248||DOI: 10.1093/cid/cit719|
|Includes FDA Authors from Scientific Area(s): Drugs|
|Entry Created: 2013-11-02||Entry Last Modified: 2014-03-22|